Nimbus Therapeutics has reined in $65 million in new capital to fund its virtual drug discovery and development pipeline and expand into new targets in immunology, oncology and metabolic diseases.
Atlas Venture, a leading early stage biotech venture capital firm, today announced that Andrea Armstrong has joined as chief talent officer. Andrea will lead the talent acquisition efforts for Atlas and work closely with companies incubating at Atlas and across the emerging portfolio on recruiting and organizational development.
The private biotech sector is awash in capital today: funding over the last few quarters has been record-breaking, up over 250% since 2013, as biotech CEOs have worked hard to strengthen their companies’ balance sheets. But in the process of filling up their corporate coffers, have they also filled up their own wallets?
Two Atlas portfolio companies that are transforming the way cancer is treated, Surface Oncology and Unum Therapeutics, completed successful IPOs in the spring of 2018. Both had concurrent private placements from key pharmaceutical partners, and both will be advancing clinical stage programs with the new financings.
It’s heresy to write this but it’s trains not bicycles that come to mind when describing our partnering strategy at Bicycle Therapeutics. We’re looking to speed Shinkansen-style towards our goal of being an integrated oncology company while monetizing the platform and building an engine for future growth in additional diseases. We can only do this by establishing partnerships both inside and outside of our core therapeutic area. Partnering outside of your core expertise can be challenging since you are pitching early-stage data from your lead therapy area, the relevance of which may not be immediately apparent. Despite these constraints, we’ve stayed on the tracks by applying four key principles:
This blog post was written by Ros Deegan, CBO of Bicycle Therapeutics, as part of the From The Trenches feature of LifeSciVC.